KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
−1.50%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 13.77x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.85x
- Price / sales
- 14.78x
- Price / cash flow
- -4.62x
Enterprise value
- Enterprise value
- -$20.0M
- EV / sales
- -1.33x
- EV / EBITDA
- 0.24x
- EV / EBIT
- 0.20x
- Market cap
- $221.9M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026